Major study shows new insights into lasting impacts of COVID‐19 on UK population | Imperial News

Tens of thousands of people in England may have lasting symptoms from COVID‐19 more than a year
after infection, new analysis reveals.

The findings come from a representative sample of more than a quarter of a million people in England surveyed as part of the REACT study, who self-reported their symptoms and the impact of COVID-19 on their health and quality of life.

The work, led by researchers at Imperial College London, finds that while the vast majority of people recovered from infection within two weeks, a significant proportion of the group (7.5%) reported persistent symptoms lasting 12 weeks or more (Long COVID), and 5% reported symptoms lasting more than a year.

Long COVID

The most common lasting symptoms were mild fatigue, difficulty thinking or concentrating and joint pains. But other persistent symptoms reported included loss or change of sense of smell or taste, shortness of breath, severe fatigue, chest tightness or pain, and poor memory.

The variant of SARS-CoV-2 people are infected with, the initial severity of their symptoms, and whether they have pre-existing health conditions all have an impact on whether they will develop lasting symptoms. Professor Paul Elliott School of Public Health

People were more likely to report symptoms for a long time after their initial infection if they were female, had severe initial symptoms, were infected earlier in the pandemic, or had pre-existing health conditions.

Some of these symptoms were also quite often reported by people who did not have previous COVID-19.

However, mental health and health-related quality of life were worse among participants with ongoing persistent symptoms post-COVID compared with those who had never had COVID-19 or had recovered.

According to the researchers, the analysis provides a snapshot of the continued impact of COVID-19 in the UK.

They highlight that while SARS-CoV-2 infections are typically short duration, a significant proportion of adults will continue to experience persistent illness (Long COVID) that in some cases may last for over a year or more.

But they highlight that a sizeable proportion still fully recover after a prolonged period.

The findings are published today in the journal Nature Communications.

Lasting symptoms

Professor Paul Elliott, Chair in Epidemiology and Public Health Medicine from the School of Public Health at Imperial College London, said: “Our latest findings from the REACT study offer further insights into the underlying factors which are associated with prolonged symptoms after initial COVID-19.

“We find that the variant of SARS-CoV-2 people are infected with, the initial severity of their symptoms, and whether they have pre-existing health conditions all have an impact on whether they will develop lasting symptoms.”

REACT study
The findings are based on survey responses from people signed up to the REACT study. REACT was set up to track the prevalence of SARS-CoV-2 infections and immunity in the community. Pictured are the antibody test kits used as part the REACT-1 study (Credit: Imperial / Thomas Angus)

In the latest analysis, the team collected follow up survey responses from 276,840 adults in England who registered for the REACT study. Of these, 59% reported testing positive for COVID-19 between 2020 and 2022. 

Analysis shows the average duration of symptomatic illness was around 10 days, but 1 in 10 people in the study reported symptoms for more than 4 weeks, 1 in 13 for more than 12 weeks, and 1 in 20 for more than a year.

The analysis showed that almost a third of people reporting symptoms at 12 weeks will have recovered within a year.

The study has shown some big variation in people’s symptoms post-COVID. Professor Helen Ward School of Public

Among those whose lasting symptoms had fully resolved, people reported health status similar to those with shorter recovery, or who had never had COVID-19.

According to the researchers, analysis also shows that people infected in the Omicron wave of the pandemic were 88% less likely to experience symptoms longer than 4 weeks post-infection, compared to earlier waves.   

Dr Christina Atchison, Principal Clinical Academic Fellow within the School of Public Health and first author on the study, said: “While the landscape has changed considerably since the early peak of the COVID-19 pandemic, this analysis shows that a proportion of adults are still experiencing lasting symptoms.

“Importantly, we find that compared to wild type virus, those infected when Omicron was dominant were far less likely to report symptoms lasting beyond 12 weeks. This may reflect the changing levels of immunity in the population from previous exposure to the virus and vaccination.” 

Professor Helen Ward, from the School of Public Health at Imperial College London, said: “The study has shown some big variation in people’s symptoms post-COVID. While we have gained valuable insights into the groups at risk of lasting symptoms, we are undertaking detailed interviews to further understand the variation in people’s experiences and the impact on their everyday lives.

“We are also planning further follow-up of people involved in the REACT studies to assess the broader longer-term impact of the pandemic on health and well-being.”

This work was funded by the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) in support of the REACT-GE (Genomics England) and REACT-LC (Long COVID) studies, with additional support from the Huo Foundation.

The REal-time Assessment of Community Transmission (REACT) research programme was commissioned and funded by the Department of Health and Social Care in England and led by Imperial College London with logistic support from Ipsos, and infrastructure support from the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre (BRC).

‘Long-term health impacts of COVID-19 among 242,712 adults in England’ by Atchison, C., et al. is published in Nature Communications. DOI: https://doi.org/10.1038/s41467-023-41879-2

Leave a Reply

Your email address will not be published. Required fields are marked *